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analyzed for 365 days after and before the accrual period. RESULTS: On a total of 
2,962,498 subjects observed, 594 patients were hospitalized for melanoma (53.4% 
males) during 2009 (prevalence rate: 20.0 per 100,000). Among them, 43% had at 
least one chronic comorbidity, hypertension is the most common (14.6%) 
followed by combination of dyslipidemia and hypertension (3.0%). Therapy for 
melanoma is made both in and outside the hospital. Interferon alfa-2b was the 
most prescribed treatment outside the hospital with an average cost of €110, 
followed by Temozolomide (€40.7) and Erythropoietin (€39.6). During one-year of 
follow-up, 13% of patients was hospitalized for chemotherapy with an average 
cost of €7398. This amount covers also drug treatment cost during 
hospitalization. The average yearly cost/patient for population with melanoma 
was €4777 (hospitalizations: 70.8%, drugs: 14.4%, diagnostic examinations: 
14.8%), with an higher cost for the subgroup of patient already in treatment the 
previous year before the accrual period (€6156 vs €4361). If we consider the 
subgroup of patient with metastatic melanoma (N=176), the overall cost rises at 
€15,984, most of it (60%) due to drug costs for specific therapy of melanoma and 
chemotherapy. Surprisingly methotrexate and cyclophosphamide appear in the 
top five list of prescribed drugs. CONCLUSIONS: This study shows high cost of 
patients with melanoma and how real world practice therapy, especially for 
metastatic melanoma, seems to be far from the guidelines recommendation. 
This suggests to create a regional network to correctly redirect therapeutic 
choices.  
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OBJECTIVES: Diabetes mellitus (DM) is recognised as a major health problem. Its 
chronic nature and complications make it a costly disease. The aim of this study 
is two-fold: (1) to describe the methods used in the identified cost-of-illness (COI) 
studies of DM and (2) to summarise their study findings regarding the economic 
impact of DM. METHODS: This is a systematic review of MEDLINE and Scopus 
journal articles reporting the cost of type-1 and/or type-2 DM that were 
published in English from 2007 to 2011. Costs reported in the included studies 
were converted to US dollars for comparison purposes. RESULTS: The systematic 
search yielded 30 articles that met the predetermined criteria. The studies varied 
considerably in their study design, perspective and included cost categories. 
Estimates for the total annual costs of DM ranged from US$141.6 million to 
US$174 billion; direct costs ranged from US$150 to US$14,060 per patient per year 
(pppy) whereas indirect costs ranged from US$39.6 to US$7,164 pppy. Inpatient 
cost was the major contributor to direct cost in half of the studies that included 
inpatient costs, physician services and medications. In addition, patients with 
DM consumed significantly more health care resources and incurred higher 
health care costs than patients without DM. CONCLUSIONS: There is a 
considerable economic burden associated with DM, not only on the health care 
system, but also on the individual and society as a whole. Future research should 
focus on improving methods of estimating costs, enhancing the interpretation of 
study findings and facilitating comparisons between studies.  
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OBJECTIVES: To evaluate the cost of Pulmonary Arterial Hypertension (PAH) to 
health services in Mexico based on epidemiological trends, to project this 
estimate to 2012. METHODS: Retrospective medical chart review using data from 
the NIC. Clinical and resource utilization data for all patients admitted to the NIC 
with PAH between January 1, 2009 and 2011 were collected and the mean 
treatment costs per person were calculated by assigning appropriate unit cost 
data to all resource use. A prevalence based approach was used to estimate the 
economic burden of PAH. Contemporary data were obtained from 
epidemiological studies, government datasets, and other sources to estimate 
prevalence. National costs (US dollar 2012) of treatment for PAH were estimated 
by extrapolation of mean cost estimate per person to national incidence data for 
PAH. Because of uncertainties surrounding some of our estimates such as 
prevalence, one way sensitivity analyses were undertaken. RESULTS: A total of 
113 PAH patients were identified and their demographic and clinical 
characteristics, patterns of care were examined. The mean age was 38 years, and 
83% were female. The average per patient annual cost was $ 10,869 without 
specific treatment (min $ 137; max $155,928). The annual cost for the treatment 
of a single PAH patient per year with specific therapy (Bosentan) was calculated 
in $31.433. Aggregate national health care expenditures for treatment of PAH 
were USD 46.6 million In multivariate analysis, length of hospital stay, stay in 
ICU, were all significant independent predictors of treatment CONCLUSIONS: 
Treatment costs of PAH in Mexico are substantial and primarily driven by the 
intensity of hospital treatment. With the expected increase in the incidence of 
PAH in Mexico over the coming decades, these results emphasize the need for 
effective preventive and acute medical care.  
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OBJECTIVES: The current study aimed to examine direct medical cost and 
humanistic outcome of diastolic heart failure (DHF) management in Hong Kong. 
Whether the presence of comorbidities, including hypertension, diabetes and 
renal impairment, affect the cost and humanistic outcome was also evaluated. 
METHODS: Retrospective, non-randomized study design was adopted. Subjects 
were recruited from the Heart Failure Registry of the Prince of Wales Hospital in 
Hong Kong between 2006 and 2008 and completion of the Minnesota Living with 
Heart Failure Questionnaire (MLHFQ) at 3 designated time pints to be eligible. 
Patients with significant valvular disorder were excluded. One year medical 
records since admission were reviewed. Heart failure related admissions, clinic 
visits, cardiovascular drugs, laboratory and diagnostic tests were recorded. The 
costs and MLHFQ scores in patients with or without hypertension, diabetes, and 
renal impairment were compared. Non-parametric Wilcoxon Signed Rank and 
Mann-Whitney tests were used. A p-value < 0.05 was considered statistically 
significant. RESULTS: A total of 73 DHF patients were included. The mean 1-year 
direct medical cost was USD 20,098 (1 USD = 7.75 HKD), with in-patient care cost 
contributing to the largest proportion (72.2%) of the total cost. Patients with 
diabetes or renal impairment were associated with a higher cost of DHF 
management. Significant difference was found in the renal impairment group 
(median cost: USD 24,763 versus USD 12,789 in no impairment group, p=0.023). 
The mean MLHFQ scores of the subjects improved significantly from baseline 
30.81±13.89 to 12 months 15.84 ±11.32 (p<0.0005). CONCLUSIONS: The cost of 
management of DHF was shown to be enormous and further increased in the 
presence of comorbidities. With the aging population in Hong Kong, the 
incidence of DHF is expected to increase progressively. Further studies are 
demanded to guide more optimal medical resource allocation for DHF 
management.  
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OBJECTIVES: Prostate cancer is the second leading cancer diagnosed among 
men. In Spain the incidence of prostate cancer was 100.4 cases per 100,000 
males. Advanced prostate cancer is cancer that has spread outside of the 
prostate capsule and may involve other parts of the body, most commonly to the 
lymph nodes and bones . The aim of this study was to estimate the lifetime costs 
of a cohort of advanced prostate cancer patients diagnosed in Spain in 2012. 
METHODS: An economic model was developed in EXCEL incorporating Spanish 
incidence, mortality and cost data supplemented with data from the 
international literature. Progression from Stage III to Stage IV was permitted. 
Costs were discounted. Lifetime costs were presented on an individual basis and 
for the entire cohort of newly diagnosed Stage III and Stage IV prostate cancer 
patients. RESULTS: Lifetime costs for advanced prostate cancer were 
approximately 23,032 € per patient. Using the projected incident cases for 2012, 
the total cost for the incident cohort of patients in 2012 would amount to 172 
million euros. These results were more sensitive to changes in the ongoing costs 
(post initial 12 months) of Stage III prostate cancer, the rate of progression from 
Stage III to Stage IV and the discount rate applied to costs. CONCLUSIONS: This 
study provides an estimate of the lifetime costs of advanced prostate cancer in 
Spain and a framework for further research. Until improved long-term 
prospective or observational data do become available the current results 
indicate that the burden of advanced prostate cancer is substantial and will 
increase due to an increasing number of new cases and reductions in mortality. 
Any treatments that could potentially reduce the economic burden of the disease 
should be of interest to health care decision makers given the context of limited 
resources in Europe.  
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OBJECTIVES: To evaluate the health care cost of diabetes with co-morbidities by 
using cost of illness analysis. METHODS: A prospective observational study was 
conducted for a period of six months at Rohini super specialty hospital, AP, 
India. The patients were identified during ward rounds and by regular case 
record reviews during study period. The enrolled patients were followed from 
the day of admission till the day of discharge and the relevant study data 
including total direct costs which include direct medical costs, cost of laboratory 
investigations, cost of consultation, cost of hospitalization, direct nonmedical 
cost includes the transportation cost to hospital and indirect costs which include 
days lost from work or productivity, was documented in case record form. 
RESULTS: A total of 150 patients were enrolled during the study period. The 
average cost per diabetic patient without complications was Rs. 1623 this 
includes the average total direct medical cost was Rs.1483 (91.37%), the average 
direct non medical cost was Rs. 20 (1.23%) and the average total indirect cost was 
Rs. 120 (7.4%) compared to for those with diabetes complications, Rs. 7706 for 
macrovascular complications, Rs. 4907 for microvascular complications and Rs. 
2810 others infections. The cost for the treat diabetes with co morbidities was 
found to be Rs. 17046, the average total direct medical cost was Rs. 15738 
(92.41%), the average direct non medical cost was Rs. 204 (1.12%) and the average 
total indirect cost was Rs. 1104 (6.47%). CONCLUSIONS: Our study results 
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revealed that higest/more economic burden was found in male patients (Rs. 
18018), the age group of 51-60 years (Rs. 19184), the newly diagnosed (<1year) 
patients (Rs. 21411), the patients who stayed for 10-13 days in the hospital  
(Rs. 28406), the patients with two co-morbidities (Rs. 18935), the patients with 
agriculture as their occupation (Rs. 22306) and the patients who bearing 
macrovascular complications (Rs. 7706).  
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OBJECTIVES: Nowadays thyroid disease found in 50% of the adult population and 
80% of the elderly population of Ukraine. However there is no information about 
pharmacoeconomic analysis of this pathology. METHODS: We conducted a 
retrospective analysis of medical records of 3417 patients with hypothyroidism 
(n=2143) and diffuse toxic goiter (DTG) (n=1274), and determined the total annual 
cost of illness (COI) including direct and indirect costs. RESULTS: 12-month COI 
of hypothyroidism was $1860681.18, similar costs of DTG was $1439632.74. 
Annual direct costs of treatment per patient with hypothyroidism were $229.10, 
of which costs of investigations accounted for $62.28 (27.18%), the cost of 
medicinal treatment of the underlying disease was $27.96 (12.20%) and the cost 
of medicinal treatment of complications associated with hypothyroidism was 
$138.86 (60.62%). An indirect cost of treatment per patient with hypothyroidism 
was $639.16. The total 12-month COI of hypothyroidism per patient was $868.26. 
The total 12-month COI of DTG per patient was $1130.01, of which indirect costs 
accounted for $746.44. Annual direct costs of treatment per patient with DTG 
were $383.57, of which costs of investigations accounted for $109.50 (28.55%), the 
cost of medicinal treatment of the underlying disease was $100.45 (26.19%) and 
the cost of medicinal treatment of complications associated with DTG was 
$173.62 (45.26%). CONCLUSIONS: Thus, first held in Ukraine cost of illness 
analysis of the thyroid disease showed that the most money spent on indirect 
costs.  
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OBJECTIVES: The study objective was to provide current patient-level paid cost 
estimates for complications among adult patients with Type 2 diabetes. 
METHODS: Patients ages ≥18 with ≥1 claim for a diabetes-related complication 
were selected from the PharMetrics Health Plan Claims Database, a large U.S. 
claims database including medical and pharmacy claims for >75 million patients 
from 80 health plans, during 2009-2010. Patients were continuously-enrolled in 
the same health plan ≥12 months before and ≥24 months after the first 
complication claim and had a diagnosis of Type-2 DM prior to their first 
complication. Patients with gestational diabetes, missing cost, or Medicare 
Reimbursement or SCHIP coverage were excluded. Diabetes-related 
complications included cardiovascular events, gangrene, amputation, foot ulcer, 
renal disease, chronic kidney disease, eye disease and neuropathy. All direct 
costs in the 2-years following complications were inflated to 2011 dollars. 
RESULTS: There were 113,222 adult Type-2 DM patients identified with a mean 
age of 58 years and 53% male. The most frequent complications included 
neuropathy (27%), non-proliferative retinopathy (22%), renal disease (21%) and 
heart failure (14%). The most frequent treatments were oral antidiabetics (69%), 
antihyperlipidemics (62%), ACE-inhibitors (44%), insulins (34%) and 
antidepressants (29%). The mean (SD) total cost per patient was $38,849 ($71,253) 
[inpatient $14,086 ($45,290), outpatient $17,319 ($40,887), and pharmacy $7,443 
($12,152)]. Renal disease cost among those with renal disease averaged $20,908 
($80,294), foot ulcers costs among those with amputation/foot ulcers averaged 
$6,358 ($18,017) and heart failure costs among those with cardiovascular/ 
cerebrovascular disease averaged $5,764 ($24,384). CONCLUSIONS: Patients with 
Type 2 DM exhibited substantial health care costs associated with medical 
complications. The most costly conditions are renal disease, foot ulcers/ 
amputations and cardiovascular/cerebrovascular diseases.  
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OBJECTIVES: To compare health care costs among patients with bone metastasis 
secondary (BMS) to prostate cancer (PC) compared to a matched cohort of 
patients with PC without BM. METHODS: A retrospective analysis was performed 
using the OPTUMInsight Oncology claims database. Male patients aged ≥18 years, 
with BMS to PC between July 1, 2003 and December 31, 2011, who were insured 
by a commercial health plan were identified (first BM termed “index”). Patients 
were required to have > 6 months continuous eligibility prior to and > 6 months 
subsequent to the first PC diagnosis in the index period (January 1, 2004 - June 
30, 2010). Patients with a diagnosis of BMS to PC were identified and matched 1:1 
to PC patients without BM based on age, geographic region, payer type and year 
of study entry (index year). Patients were followed from index to death or 
database end. Study measures included health care costs. RESULTS: A total of 
1900 patients with BMS to PC were matched to 1890 PC patients without BM. 
Among those patients with BMS to PC versus those PC patients without BM, 
respectively, the mean (SD) annualized total follow-up costs per patient were 
$69,517 ($77,127) and $21,364 ($29,994). The largest proportion of mean costs 
were attributable to all other medical costs in the BMS to PC cohort (29.5%), 
followed by outpatient visits (26.4%), inpatient hospitalizations (25.9%), and total 
pharmacy costs (18.1%). Among the PC patients without BM cohort the largest 
proportion of mean costs were inpatient hospitalizations (29.6%), followed by all 
other medical costs (28.9%), outpatient visits (27.6%), and total pharmacy costs 
(12.6%). CONCLUSIONS: Patients with BMS to PC had 3.25 fold more costs 
compared to the PC patients without BM, mainly driven by inpatient and 
outpatient costs. This indicates a substantial economic burden incurred by 
patients with BMS to PC.  
 
PHS32  
COSTS ASSOCIATED WITH HOSPITAL ADMISSION FOR HEART FAILURE IN 
TWO HOSPITALS IN THE CITY OF BOGOTA, COLOMBIA  
Dennis R1, Rojas M2, Tamayo D2, Rodriguez V2, Brophy J3, Castro H2 
1Fundacion Cardioinfantil, Bogota, Colombia, 2Universidad Javeriana, Bogota, Colombia, 3McGill 
University, Montreal, QC, Canada  
OBJECTIVES: To describe the direct medical costs associated with management 
of hospital admission due to heart failure. METHODS: Cohort study of patients 
hospitalized due to heart failure during 2009 and 2010. 1426 patients with heart 
failure hospitalized in two tertiary care hospitals in Bogota that manage mainly 
patients from the Colombian contributive obligatory health care plan (workers 
and their families). All patients with a discharge diagnosis of heart failure during 
the time of the study were included. The point of view of the study was that of 
the third-party payer. Bills for each patient´s costs of care sent and accepted by 
the third party payer were quantified and broken down by cost source.  
Costs were adjusted to Colombian pesos of 2011 (US$1= COL $1,794). RESULTS: 
The hospital bills of 1426 discharged patients (352 in one hospital and 1074 in the 
second hospital) were analyzed. The mean costs associated with an event of 
hospitalization, adjusted to 2011, was COL$ 10,400,213 (SD COL$ 22,552,954; 
median 3,171,129; IQ Range: 1,506,654-6,802,384). Out of this total cost, 32,8% (SD 
20.9%) corresponded to medication costs; 26.1% (SD. 15,5%) to hospital  
stay; 13,1% (SD 12,9%) to medical fees; 12,5% (SD 9,8%) to laboratory tests, and 
18,7% (SD 13,4%) to other costs. CONCLUSIONS: Hospitalizations costs in 
Colombia due to heart failure are substantial and highly variable, when 
compared with those for other conditions. The main driver of these costs is 
medication use. This study should set the basis for the estimation of the cost-
effectiveness of interventions that decrease the rate of hospitalization or the 
length of stay of these patients.  
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OBJECTIVES: To evaluate the resource use and associated costs of patients 
treated for polycythemia vera (PV), myelofibrosis (MF) and essential 
thrombocythemia (ET) in the Brazilian public health care system. METHODS: 
DATASUS is a Brazilian comprehensive database that reports all outpatient and 
inpatient services provided by the Brazilian public health care system. Patients 
identified with the diagnosis of PV (ICD 10 D45), MF (D47.1) and ET (D47.3) in the 
Datasus database between January 2010 and December 2010 were included in the 
analysis, irrespective of the date of diagnosis. Patients’ profile was defined based 
on age, sex and geographical region. Costs and resource use patterns were 
analyzed for the year 2010 and characterized by the percentage of patients using 
each health resource, the average quantity per patient and the total associated 
cost. Analyses were segmented by outpatient (drugs and transport) and inpatient 
(hospitalization) costs. RESULTS: The number of patients identified with the 
diagnosis of PV, MF and ET were 1533, 2130 and 2413, respectively. Their average 
age was 65, 63 and 63 years, and the percentage of females equaled 55%, 55% and 
66%, respectively. The majority of patients live in the southeast region of Brazil. 
The three diseases present a similar treatment pattern. The majority of 
outpatient costs are associated to first line and second line chemotherapy 
treatment (21.9% and 77.5% for PV; 12.6% and 86.9% for MF; 12.6% and 87.2% for 
ET, respectively). The average annual outpatient and inpatient costs per patient 
were: R$2,581.27 and R$15.27 for PV; R$3,341.02 and R$45.22 for MF; R$ 4,070.28 
and R$15.92 for ET) (1 USD = R$2.04). CONCLUSIONS: The current treatment for 
PV, MFand ET in the Brazilian public health care system relies basically on the 
use of first and second line chemotherapy. These items are responsible for more 
than 90% of the annual treatment cost.  
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OBJECTIVES: Lifestyle intervention is effective in reducing the risk of 
hypertension and diabetes. Previous studies suggested such an intervention, if 
targeted to persons with prediabetes alone (defined by HbA1c of 5.7-6.3% or 
fasting plasma glucose of 110-125 mg/dL), was cost-saving but would take more 
than 20 years to recoup the intervention costs. Health plans typically have much 
shorter planning horizons. Therefore, a more selective population might be 
